Navigation Links
New patient satisfaction study with budesonide/formoterol combination therapy
Date:5/20/2008

Wilmington, DE May 20, 2008 A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM).1 Patients participating in the study were ages 18 years and older with moderate to severe asthma and had been previously treated with inhaled corticosteroids.1 Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.

Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p<0.001), dosing management (p<0.001), and timely relief of symptoms (p=0.037).1 Patients receiving budesonide/formoterol combination therapy fixed dose reported significantly greater satisfaction for timely relief of symptoms (p=0.002) and feeling the medication begin to work (p=0.02) compared to patients receiving fluticasone/salmeterol combination therapy.1 Budesonide/formoterol combination therapy is not indicated for adjustable dosing in the U.S.

These data showed that patients treated with budesonide/formoterol combination therapy fixed dose were more satisfied with the timeliness of their symptom relief than those patients treated with fluticasone/salmeterol combination therapy, said lead investigator Richard OConnor, MD, of the University of California-San Diego.


'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1

Related medicine news :

1. COPD patients benefit more from pulmonary rehab in earlier stages
2. New treatment gives hope for pulmonary fibrosis patients
3. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
4. Medication may prevent depression in patients with head and neck cancer
5. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
6. Bypass not to blame for heart patients mental decline
7. Long-term cognitive decline in bypass patients not due to surgery
8. Clear racial discrepancies exist among patients with CKD
9. Drug brings relief for many IBS patients who experience constipation
10. Depression, PTSD Common Among Lung Transplant Patient Caregivers
11. Depression and PTSD symptoms in caregivers of lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... PITTSBURGH, PA (PRWEB) , ... July 26, 2017 , ... ... braces,” said Dr. Ahmed Mauassra, from San Jose, Calif., “so we invented the MAGNETIC/ ... remove the bracket portion of orthodontic braces. In doing so, it offers an effective ...
(Date:7/26/2017)... ... July 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization ... affected by diabetes, is excited to announce the 106 college athletes with type 1 ... Established in 2005, the Team Type 1 Foundation has bestowed a total of 271 ...
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol International ... cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces the ... to June 30, 2017. Iso International LLC recorded unaudited fiscal Q1 profits of ...
(Date:7/26/2017)... ... , ... The number of adults 65 years or older is expected to ... control in the population are not well described. In a study published in The ... of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors associated ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist ... to provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the ... the ability to develop the Pharmacist eCare Plan, a shared document detailing a ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology: